Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18690044 | 0.98 | TSHR (0.41) | TSHRKDM1AMAOBRCOR1CYP2D6 | |
| SCHEMBL24718199 | 0.89 | TSHR (0.47) | TSHR | |
| SCHEMBL20941865 | 0.88 | OPRM1 (0.34) | TSHRKDM1AMAOBRCOR1CYP2D6 | |
| SCHEMBL23997226 | 0.86 | OPRM1 (0.37) | OPRM1OPRL1CHRM2CHRM3SMN1; SMN2 | |
| SCHEMBL13339791 | 0.84 | TSHR (0.41) | TSHRKDM1AMAOBRCOR1CYP2D6 | |
| SCHEMBL20941868 | 0.83 | PIK3CD (0.39) | TSHRKDM1AMAOBRCOR1CYP2D6 | |
| Hydrochloric Acid SCHEMBL3494601 | 0.82 | TSHR (0.44) | TSHRKDM1AMAOBRCOR1CYP2D6 | |
| SCHEMBL20941857 | 0.80 | OPRM1 (0.38) | CYP2D6ALDH1A1HPGDHSD17B10OPRM1 | |
| SCHEMBL347358 | 0.80 | CTSB (0.37) | TSHRALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL10127159 | 0.78 | CYP3A4 (0.34) | KDM1AMAOBRCOR1CYP2D6OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12202843-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-11034704-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2021-06-15 | — | — | US | disclosed |
| EP-3119396-B1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2021-05-05 | — | — | EP | disclosed |
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ALLERGAN, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| US-10428088-B2 | Muscarinic receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ALLERGAN, INC. | 2019-04-25 | — | — | US | disclosed |
| US-10030035-B2 | Muscarinic receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-10030035-B2 | Muscarinic receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-07-24 | — | — | US | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | NXERA PHARMA UK LIMITED (GB) | 2017-04-06 | — | — | US | disclosed |
| WO-2015140559-A1 | MUSCARINIC RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2015-09-24 | — | — | WO | disclosed |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096437-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | TSHR 90/4885KDM1A 1865/4885MAOB 403/4885 |
| US-10428088-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | TSHR 94/4885KDM1A 1848/4885MAOB 404/4885 |
| US-20220048928-A1 | MUSCARINIC RECEPTOR AGONISTS | CHRM1, CHRM2, CHRM3 | TSHR 94/4885KDM1A 1848/4885MAOB 404/4885 |
| US-12202843-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | TSHR 94/4885KDM1A 1848/4885MAOB 404/4885 |
| US-10030035-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | TSHR 90/4885KDM1A 1865/4885MAOB 403/4885 |
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | SSTR5, SSTR2, GPR119 | TSHR 45/4885KDM1A 4375/4885MAOB 395/4885 |
| US-10501483-B2 | Enamines and diastereo-selective reduction of enamines | ENY2, PNMT, CHRM1 | TSHR 1550/4885KDM1A 596/4885MAOB 221/4885 |
| US-20190119304-A1 | ENAMINES AND DIASTEREO-SELECTIVE REDUCTION OF ENAMINES | ENY2, PNMT, CHRM1 | TSHR 1550/4885KDM1A 596/4885MAOB 221/4885 |
| US-11034704-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | TSHR 94/4885KDM1A 1848/4885MAOB 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.